For people whose depression hasn’t improved with antidepressants, transcranial magnetic stimulation (TMS) offers an evidence-based treatment option with encouraging, though varied, results. Published research indicates that approximately 60 to 65% of patients may experience a clinically meaningful improvement after treatment, a figure regarded as a conservative estimate.
Researchers assess TMS effectiveness through response and remission rates. A response ‌refers to a reduction of at least 50% in depression symptom severity. Remission occurs when a patient’s score falls below the defined threshold for depression on a recognised assessment scale.
The distinction matters because substantial improvement doesn’t always mean complete remission. Evidence shows that TMS can work for many people with depression, including those who haven’t benefited from medication, although it’s neither immediate nor effective for everyone.
What the Numbers Show
Published TMS rates vary according to the outcome measured, the treatment protocol, the patient group, the assessment scale, and the follow-up period used.
Across available research, the TMS therapy success rate is approximately 60 to 65% for clinically meaningful improvement. This figure is considered a conservative estimate rather than a prediction for an individual patient.
Real-world registry data reported response rates of approximately 58–83% and remission rates of approximately 28–62%, depending on the assessment scale. People with treatment-resistant depression may experience results towards the lower end because previous treatment resistance can make the condition harder to treat.
Response and remission represent different levels of improvement, so understanding each term helps patients interpret published TMS results more accurately:
- Response: Depression symptoms decrease by at least 50% from the patient’s starting score on a recognised rating scale.
- Remission: Symptoms fall below the scale’s specified threshold, meaning the patient no longer meets that measure’s criteria for an active depressive episode.
The distinction explains why studies may report a strong response rate alongside a lower remission rate. Someone can improve substantially without becoming symptom-free.
For people who have tried several antidepressants, the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial provides valuable comparative context. Response rates declined with each successive medication trial.
| Treatment stage | What the stage represents | Reported response rate |
|---|---|---|
| First antidepressant trial | The first medication used to treat the current depressive episode in the STAR*D trial. | Approximately 40%. |
| Second antidepressant trial | A different medication tried after the first treatment didn’t provide satisfactory improvement. | Approximately 25%. |
| Third antidepressant trial | Another medication tried after two previous treatments didn’t provide satisfactory improvement. | 16.8% |
| TMS treatment | Clinically meaningful improvement reported in published TMS research. | Approximately 60 to 65%, considered a conservative estimate. |
Antidepressants help many people and remain an established part of depression care. For those whose symptoms persist despite several medication trials, the comparison shows why TMS may be a clinically supported next step. Medication changes should always be discussed with the treating doctor.
TMS Results for Treatment-Resistant Depression
Antidepressant medication alone typically produces a response in around 50% of patients and remission in just over 35%, figures that decline further with each unsuccessful trial, as the STAR*D data above shows.
For treatment-resistant depression specifically, more advanced TMS protocols have shown stronger results. A double-blind randomised controlled trial of Stanford Neuromodulation Therapy (SNT), an accelerated form of TMS, found markedly higher one-month remission rates compared with sham treatment in patients with treatment-resistant depression.
A 2024 case-control study reported an 80% response rate and a 64% remission rate for intermittent theta burst stimulation (iTBS) used alone, figures comparable to combined iTBS with antidepressants (74% response, 58% remission) in the same study.
The time required to notice improvement also differs between patients. The TMS response timeline explains when changes may emerge during a standard treatment course.
Why TMS Works When Medication Hasn’t
Rather than using the same systemic mechanism as medication, TMS treats depression by stimulating specific brain regions involved in mood regulation. During treatment, an electromagnetic coil rests against the scalp and delivers repeated magnetic pulses to the selected area.
How does TMS target mood-regulating brain networks?
During depression treatment, the TMS coil delivers magnetic pulses through the skull to the dorsolateral prefrontal cortex, which helps regulate mood, motivation, and decision-making. This region often shows lower metabolic activity in people with depression.
Each magnetic pulse creates a small electrical current in the underlying brain tissue. The current activates neurons in the prefrontal cortex and influences connected regions involved in emotional regulation. Repeated stimulation aims to increase activity within this underactive network rather than affecting the entire brain.
How does neuroplasticity support improvement?
Repeated TMS pulses promote synaptic plasticity, enabling neurons to strengthen existing connections and form new pathways within the targeted network. A full treatment course stimulates these neurons thousands of times, giving the brain repeated opportunities to reinforce healthier patterns of activity.
These changes may improve communication between the prefrontal cortex and other regions involved in mood regulation. The effect develops over multiple sessions, which explains why improvement usually occurs gradually rather than after one appointment.
Antidepressants primarily influence chemical signalling between neurons, while TMS directly changes electrical activity within selected brain networks. Someone who hasn’t responded to medication may still respond to TMS because the treatments act through different mechanisms.
What happens during mapping and theta burst treatment?
During the initial mapping session, the clinician places the coil over the motor cortex and gradually adjusts the stimulation intensity until it produces a visible thumb or finger movement. The lowest intensity that consistently produces this response becomes the patient’s motor threshold.
Clinicians use that threshold to calculate an individual treatment dose. They then reposition the coil over the prefrontal treatment area associated with depression. Mapping accounts for differences in brain anatomy and sensitivity rather than applying the same stimulation intensity to every patient.
Intermittent theta burst stimulation uses groups of rapid pulses arranged in a pattern based on naturally occurring theta brain rhythms. This protocol delivers the required stimulation in shorter treatment sessions than conventional repetitive TMS while targeting the same mood-regulating network. The clinician selects the protocol according to the patient’s assessment, treatment history, and prescribed care plan.
Is TMS Therapy Safe?
For appropriately screened patients, TMS is considered relatively safe, with mostly mild, temporary side effects and no identified long-term effects to date.
Treatment doesn’t require surgery, general anaesthesia, sedation or hospital admission. Patients remain awake throughout each session and can usually drive, work, and resume normal activities immediately afterwards. Complications can occur, but they remain rare when clinicians identify risk factors before treatment and follow established stimulation protocols.
Most side effects are mild and short-lived. Around one in ten patients notice scalp tenderness or discomfort at the treatment site, which can usually be eased by repositioning the coil, and an occasional mild headache may follow a session and respond to simple pain relief.
Seizures are the most serious potential risk, but they are extremely rare, occurring in roughly one in 50,000 to 60,000 sessions among people without seizure risk factors, which is why careful screening before treatment is essential. For this reason, TMS is not suitable for everyone. It is avoided in people with epilepsy or a history of seizures and in people who have ferrous (magnetic) metal implants in the head or neck area, such as aneurysm clips or certain cochlear implants. Standard dental fillings, non-ferrous implants and metal elsewhere in the body are usually not a barrier, although every situation is assessed individually before treatment begins.
TMS is an established treatment rather than a new or experimental one. It has been used in clinical practice for four decades, is supported by over 35 years of published research, received United States FDA approval for depression in 2008, and has been listed on Medicare in Australia since November 2021.
Some people considering TMS come across alarming personal accounts online. Reading a balanced, evidence-based response to the concerns behind negative TMS stories can help place those experiences alongside the wider clinical evidence.
Which treatment history may indicate TMS?
When a person has tried at least two antidepressants without sufficient improvement, TMS for treatment-resistant depression may become an appropriate clinical consideration. The medicines may never have worked, may have stopped helping, or may have caused side effects the patient couldn’t tolerate.
Potential candidates may include people who:
- Experienced limited improvement: Two or more appropriate antidepressant trials didn’t provide adequate symptom relief.
- Lost an earlier response: Medication helped initially, but depressive symptoms later returned or became harder to manage.
- Had difficult side effects: Sexual dysfunction, emotional blunting, or other effects made continued treatment challenging.
- Prefer a drug-sparing approach: The patient wants to explore a non-invasive option after discussing available treatments with their doctor.
Why is an individual assessment needed?
No single patient profile can predict treatment response, so an individual assessment must consider the factors that may influence each person’s result. These factors include depression severity, previous treatment resistance, stimulation protocol, treatment adherence, and individual brain differences.
A thorough assessment comes before treatment. The clinician reviews the person’s diagnosis, medication history, previous therapies, physical health, and contraindications. They can then explain whether TMS is appropriate and what a realistic outcome may look like.
TMS may form one part of a wider care plan. Psychological therapy, medication, sleep, exercise, and nutritional support can continue to contribute to recovery. Patients should make medication decisions with their doctor rather than reducing or stopping treatment independently.
The Honest Limitations
Although TMS can provide substantial symptom relief for many people with depression, some patients experience limited improvement or no response after treatment. Even among responders, improvement can develop gradually and may not lead to full remission.
What time commitment does TMS require?
A standard first course includes frequent appointments over several weeks, requiring patients to consider the practical time commitment before beginning treatment. The course involves 35 sessions delivered three to five times each week over approximately four to seven weeks. Appointments last about 20 minutes, although timing varies by protocol.
Regular attendance matters because the course relies on repeated stimulation. Travel, work, caring responsibilities, and fatigue can make that schedule difficult. Extended clinic hours before and after standard working hours can help patients fit appointments around existing commitments.
Can symptoms return after TMS?
While some patients experience benefits for an extended period after completing TMS, depressive symptoms can return and require further clinical support. Some responders later need another course, maintenance sessions, medication, psychotherapy, or a combination of treatments. A clinician should assess returning symptoms and recommend the next step.
The long-term effects of TMS depend on the patient’s condition, response, and ongoing care. The treatment shouldn’t be presented as a permanent cure or as a replacement for other forms of support.
TMS may also feel uncomfortable for some patients, despite its ‌favourable tolerability. Scalp tenderness, facial muscle movement, or a temporary headache can occur. Clinicians can often improve comfort by adjusting the coil position or treatment settings.
Weighing these factors helps patients make a considered decision. A detailed overview of the benefits and practical drawbacks of TMS can support that discussion with a healthcare professional.
Does Medicare Cover TMS?
Through four Medicare Benefits Schedule (MBS) items, eligible adults can receive benefits for the mapping and delivery of initial and retreatment rTMS courses. These items have applied since 1 November 2021 and relate specifically to major depressive episodes meeting the stated treatment-resistance criteria.
Eligibility for an initial course requires the patient to:
- Have no previous TMS treatment: The patient must not have received TMS in a public or private setting.
- Be at least 18 years old: Initial-course Medicare benefits apply to adults.
- Have a major depressive episode: A psychiatrist must confirm the diagnosis using the relevant clinical criteria.
- Have tried at least two antidepressant classes: Each medicine must generally have been taken at the recommended therapeutic dose for at least three weeks, unless contraindicated.
- Complete the required treatment checks: A clinician must assess adherence, use the maximum tolerated therapeutic dose where appropriate, and confirm psychological therapy where clinically suitable.
A general practitioner or psychiatrist can provide the referral for item 14216. An additional referral isn’t required when the patient already has a therapeutic relationship with the rTMS-trained psychiatrist.
Which MBS items cover rTMS?
Once the psychiatrist confirms eligibility and suitability, the applicable item depends on whether the patient is starting an initial course or retreatment.
| MBS item | Covered rTMS service |
|---|---|
| 14216 | Psychiatrist-prescribed and treatment-mapped for an initial course. |
| 14217 | Delivery of an initial course of up to 35 treatment sessions. |
| 14219 | Psychiatrist’s prescription and mapping for a retreatment course. |
| 14220 | Delivery of a retreatment course of up to 15 treatment sessions. |
Mapping under items 14216 and 14219 must be performed personally by an appropriately trained psychiatrist. Treatment under items 14217 and 14220 may be delivered by that psychiatrist or a trained healthcare professional working on their behalf.
Most patients receive rTMS as outpatients or in consultation rooms, although Medicare benefits can also apply in a hospital when the psychiatrist certifies that admission is required. Medicare doesn’t currently fund TMS for conditions such as obsessive-compulsive disorder, post-traumatic stress disorder, or anxiety.
Medicare pays the scheduled benefit but doesn’t automatically guarantee that every provider will charge no gap. Neuralia TMS offers a no out-of-pocket option for eligible patients who meet the treatment-resistant depression criteria.
Medicare requirements and scheduled fees may change. Patients should confirm their eligibility, referral needs, and costs with the clinic and treating doctor before beginning a course.
Find Out Whether TMS Is Suitable for You
Suitability depends on your medical history, previous treatments, and individual needs, so Neuralia TMS begins with a thorough clinical assessment before recommending treatment. The resulting plan reflects your clinical presentation and assessment findings.
Eligible patients with treatment-resistant depression may access a no-out-of-pocket TMS option through Medicare. The clinical team can explain eligibility, expected time commitments, and safety considerations before you decide whether to proceed.
Contact Neuralia TMS or call (08) 6230 3996 in Western Australia or (03) 9122 5246 in Melbourne to request an assessment.
FAQs On Does TMS Therapy Actually Work
How effective is TMS therapy for depression?
Published research indicates that approximately 60 to 65% of patients may see a clinically meaningful improvement after TMS, a figure considered conservative, though individual results vary. Effectiveness is judged through both response and remission, so an individual assessment is the best guide to what the evidence means for a particular person, without predicting or guaranteeing a result.
Does TMS work for treatment-resistant depression?
For people whose depression hasn’t responded adequately to at least two antidepressants, TMS is an evidence-based option that works differently from medication by targeting brain networks involved in mood regulation. Treatment resistance can make depression harder to treat, so improvement isn’t guaranteed, and a psychiatrist must confirm clinical suitability and Medicare eligibility before treatment begins.
Is TMS therapy safe?
For appropriately screened patients, TMS has a favourable safety profile with no long-term side effects identified to date; most effects are mild and short-lived, such as scalp tenderness (about one in ten patients) or an occasional headache, while seizures are extremely rare (roughly one in 50,000 to 60,000 sessions). It isn’t suitable for everyone, so a thorough assessment first checks for contraindications like epilepsy, a seizure history, or ferrous metal implants in the head or neck.
Back to Top : Does TMS Therapy Actually Work?

























